There is a new reality in Italy that is likely to affect all of Europe, as was the case with Lomitapide.
“Evinacumab is reimbursed as an adjunct to diet and other therapies aimed at reducing low-density lipoprotein cholesterol (LDL-C) for the treatment of adult and adolescent patients aged 12 years and older with a diagnosis of homozygous familial hypercholesterolemia (HoFH) with a null/null mutation and/or who are not at LDL-C target after treatment with evolocumab or are not at LDL-C target or have not tolerated treatment with lomitapide.“
This event does not obliterate the reality of Lipoprotein Apheresis for related indications and for pregnant HoFH subjects (we are treating a successful HoFH patient pregnancy case) and pediatric cases.
The text of the Gazzetta Ufficiale is available HERE